Expertise in
4
conditions

Roland Klingenberg

Giessen, HE, DE 
Expertise in
4
conditions
Giessen, HE, DE 
OverviewLocationsClinical Research

Overview

Roland Klingenberg practices in Giessen, Germany. Mr. Klingenberg is highly rated in 4 conditions, according to our data. His top areas of expertise are Acute Coronary Syndrome, Heart Attack, Atherosclerosis, Percutaneous Coronary Intervention (PCI), and Thrombectomy.

His clinical research consists of co-authoring 275 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years.

Gender
Male

Locations

Giessen, HE, Germany
Other Locations
Bad Nauheim, HE 61231, Germany
Bad, BY, Germany
Dortmund, NW, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Phase I-II Randomized Prospective Double-blind Multi-center Trial on the Effects of a Short Course of Oral Everolimus on Infarct Size, Left Ventricular Remodeling and Inflammation in Patients With Acute ST-Elevation Myocardial Infarction
Phase I-II Randomized Prospective Double-blind Multi-center Trial on the Effects of a Short Course of Oral Everolimus on Infarct Size, Left Ventricular Remodeling and Inflammation in Patients With Acute ST-Elevation Myocardial Infarction
Enrollment Status: Completed
Publish Date: December 03, 2021
Intervention Type: Drug
Study Drug: Everolimus
Study Phase: Phase 1/Phase 2
Multi-dimensional Prevention Program After Acute Coronary Syndrome (ELIPS) (SPUM-ACS- SP1)
Multi-dimensional Prevention Program After Acute Coronary Syndrome (ELIPS) (SPUM-ACS- SP1)
Enrollment Status: Completed
Publish Date: April 30, 2020
View 1 Less Clinical Trial

275 Total Publications

Gut microbiota-derived imidazole propionate predicts cardiometabolic risk in patients with coronary artery disease.
Gut microbiota-derived imidazole propionate predicts cardiometabolic risk in patients with coronary artery disease.
Journal: European heart journal
Published: June 14, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Klingenberg's expertise for a condition
ConditionClose
View All 17 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile